Pluristem Therapeutics to Present its Clinical Trial Plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference
BUSINESS WIRE
Posted: 2008-02-19 08:24:27
NEW YORK--(BUSINESS WIRE)----Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that it will present its clinical trial plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California, USA. The presentation will take place on February 19th at 1 pm Pacific Time and will be web-cast live (at wsw.com and for 90 days following the presentation.
Mr. Zami Aberman, Pluristem's Chairman and CEO commented, "We are very glad to have the opportunity to present our cutting edge cell therapy technology and our clinical programs at the Roth Capital Partners 20th Annual OC Growth Stock Conference. We strongly believe that our PLX cells can revolutionize the treatment of hematological malignancies and peripheral artery disease (PAD) and be therapeutically beneficial to millions of people. The Company is moving forward with its clinical programs and expects to announce its progress with the FDA and the EMEA (the Federal Drug Administration and the European Medicines Agency). Our target is to start our clinical trials in humans during 2008."
About the Roth Capital Partners 20th Annual OC Growth Stock Conference
Presented by ROTH Capital Partners
February 18-21, 2008 @ The Ritz Carlton Laguna Niguel
One Ritz-Carlton Drive
Dana Point, California 92629
The Roth Capital Partners 20th Annual OC Growth Stock Conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California. The conference will consist of three focused days of presentations from over 300 small-cap companies.
About Pluristem
Pluristem Therapeutics Inc. is a company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).
Pluristem's products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta, a non-controversial source, and not from embryonic stem cells. The MSCs are expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are believed to be immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantation.
Pluristem has offices in the USA with research and manufacturing facilities in Israel. |
